부산대학교 도서관

Aims: Treatment with the wearable cardioverter defibrillator (WCD) may protect against sudden cardiac death (SCD) as a bridging therapy until a cardioverter‐defibrillator may be implanted. We analyzed in a multicenter setting a consecutive patient cohort wearing WCD to explore sex differences. Methods and Results: We analyzed 708 consecutive patients, 579 (81.8%) from whom were males and 129 (18.2%) females (age, 60.5 ± 14 vs. 61.6 ± 17 years old; p =.44). While the rate of ischemic cardiomyopathy (ICM) as a cause of prescription of WCD was significantly higher in males as compared to females (42.7% vs. 26.4%; p =.001), females received it more frequently due to nonischemic cardiomyopathy (NICM) (55.8% vs. 42.7%); p =.009). The wear time of WCD was equivalent in both groups (21.1 ± 4.3 h/days in males vs. 21.5 ± 4.4 h/days in females; p =.27; and 62.6 ± 44.3 days in males vs. 56.5 ± 39 days in females; p =.15). Mortality was comparable in both groups at 2‐year‐follow‐up (6.8% in males vs. 9.7% in females; p =.55). Appropriate WCD shocks and the incidence of ICD implantations were similar in both groups (2.4% in males vs. 3.9% in females; p =.07) (35.1% in males vs. 31.8% in females; p =.37), respectively. In age tertile analysis, compliance was observed more in 73–91 years old group as compared with 14–51 years old group (87.8% vs. 68.3%; p <.001). Conclusion: Compliance for wearing WCD was excellent regardless of sex. Furthermore, mortality and the incidence of ICD implantations were comparable in both sexes. Appropriate WCD shocks were similar in both sexes. [ABSTRACT FROM AUTHOR]